PPARGC1A and metabolic dysfunction-associated steatotic liver disease: Database analyses (Fig. 7A) showed that PGC1α expression is significantly decreased in the advanced stage of MASLD (Group 3/4/5 vs Group 0, p = 0.043; EMBL-EBI database, Accession No. E-MTAB-4856).